 | | Vol. 9.22 – 16 June, 2021 |
| |
|
|
| Researchers showed that the SARS-CoV-2 envelope protein alone was able to cause acute respiratory distress syndrome-like damages in vitro and in vivo.
[Cell Research] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Researchers showed that the SARS-CoV-2 envelope protein alone was able to cause acute respiratory distress syndrome-like damages in vitro and in vivo.
[Science Immunology] |
|
|
|
| Scientists developed a trimeric form of the receptor binding domain and showed that it induced a potent neutralizing antibody response against live virus with diverse effector functions and provided protection against SARS-CoV-2 challenge in mice and rhesus macaques.
[Nature Communications] |
|
|
|
| The authors examined the role of host innate immune defenses in restricting early SARS-CoV-2 infection using transcriptomics and biomarker-based tracking in serial patient nasopharyngeal samples and experiments with airway epithelial organoids.
[Journal of Experimental Medicine] |
|
|
|
| Researchers performed multi-omic single-cell immune profiling of 64 COVID-19 patients across the full range of disease severity, from outpatients with mild disease to fatal cases.
[Journal of Experimental Medicine] |
|
|
|
| The authors explored the set of computationally predicted SARS-CoV-2 HLA-I and HLA-II ligands, examining protein source, concurrent human/murine coverage, and population coverage.
[Genome Medicine] |
|
|
|
| Scientists investigated SARS-CoV-2 spike-specific memory B cells and their dependence on CD4+ T cell help in different settings of COVID-19.
[Cell Reports] |
|
|
|
| Utilizing HLA-peptidomics researchers were able to identify SARS-CoV-2-derived peptides presented by highly prevalent HLA Class-I (HLA-I) molecules using infected cells as well as overexpression of SARS-CoV-2 genes.
[Cell Reports] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| MGCP, in contrast to previously identified microbial cell surface polysaccharides, through a Dectin1-Cox2 signaling axis in dendritic cells, facilitated regulatory T cell induction from naïve T cells.
[Nature Communications] |
|
|
|
| To identify mechanisms of resistance to Mycobacterium tuberculosis (Mtb) infection, scientists compared transcriptional profiles from highly-exposed contacts who resisted tuberculin skin test/interferon-γ release assay conversion and controls with latent Mtb infection using RNAseq.
[Journal of Clinical Investigation] |
|
|
|
| Scientists reported that helminth parasite excretory/secretory factors termed as parasitic ligands inhibited ROS-induced NETs by blocking the activation of nonselective calcium permeable channel transient receptor potential melastatin 2.
[Scientific Reports] |
|
|
|
| Researchers reported that antibodies that displayed high levels of cross-reactivity with the SARS-CoV-2 spike, were incapable of neutralizing pseudoviruses expressing SARS-CoV-2 spike proteins and were unlikely to mediate ADE via FcγRII receptor engagement.
[Scientific Reports] |
|
|
|
|
| The authors review recent insights into the role of NK cells in viral infections, with particular emphasis on human studies.
[Nature Reviews Immunology] |
|
|
|
| Scientists review the current knowledge and crucial information about how SARS-CoV-2 attaches on the surface of host cells through a variety of receptors, such as ACE2, neuropilin-1, AXL, and antibody–FcγR complexes.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Investigators summarize what is known about the pathogenesis of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and of acute COVID-19, and speculate that the pathogenesis of post-COVID-19 syndrome in some people may be similar to that of ME/CFS.
[Trends in Molecular Medicine] |
|
|
|
|
| LetsGetChecked announced the authorization of its home collection COVID-19 test for use on anyone age two years and older with guardians supervising the self collection by minors ages 12 to 18 years and performing the sample collection for children ages two to 11 years.
[LetsGetChecked (BusinessWire, Inc.)] |
|
|
|
| Crestone, Inc. announced the first patient has been enrolled in a Phase II clinical trial of CRS3123 for the treatment of Clostridioides difficile infection (CDI).
[Crestone, Inc. (BusinessWire, Inc.)] |
|
|
|
|
| June 21 – 26, 2021
Virtual |
|
|
|
|
|
| Brigham and Women’s Hospital – Boston, Massachusetts, United States |
|
|
|
| | University of Washington – Seattle, Washington, United States |
|
|
|
| | Uppsala University – Uppsala, Sweden |
|
|
|
| | Salk Institute – La Jolla, California, United States |
|
|
|
| | Rochester Regional Health – Rochester, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
